AU2021363702A1 - Compounds and methods for the treatment of ocular disorders - Google Patents

Compounds and methods for the treatment of ocular disorders Download PDF

Info

Publication number
AU2021363702A1
AU2021363702A1 AU2021363702A AU2021363702A AU2021363702A1 AU 2021363702 A1 AU2021363702 A1 AU 2021363702A1 AU 2021363702 A AU2021363702 A AU 2021363702A AU 2021363702 A AU2021363702 A AU 2021363702A AU 2021363702 A1 AU2021363702 A1 AU 2021363702A1
Authority
AU
Australia
Prior art keywords
substituted
alkyl
radical
heteroalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021363702A
Other languages
English (en)
Other versions
AU2021363702A9 (en
Inventor
Yair Alster
Hila Barash
Charles Bosworth
Robert M. Burk
Jonathan DUNN
Marc GLEESON
Ian Holmes
Alexander James NICHOLLS
Omer Rafaeli
Mark Richard Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azura Ophthalmics Ltd
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of AU2021363702A1 publication Critical patent/AU2021363702A1/en
Publication of AU2021363702A9 publication Critical patent/AU2021363702A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021363702A 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders Abandoned AU2021363702A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063094793P 2020-10-21 2020-10-21
US63/094,793 2020-10-21
US202163170988P 2021-04-05 2021-04-05
US63/170,988 2021-04-05
PCT/IB2021/000707 WO2022084738A2 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
AU2021363702A1 true AU2021363702A1 (en) 2023-06-15
AU2021363702A9 AU2021363702A9 (en) 2024-02-08

Family

ID=81291739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021363702A Abandoned AU2021363702A1 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Country Status (8)

Country Link
EP (1) EP4232149A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546453A (cg-RX-API-DMAC10.html)
KR (1) KR20230110515A (cg-RX-API-DMAC10.html)
AU (1) AU2021363702A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196145A1 (cg-RX-API-DMAC10.html)
IL (1) IL302173A (cg-RX-API-DMAC10.html)
MX (1) MX2023004537A (cg-RX-API-DMAC10.html)
WO (1) WO2022084738A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005641A1 (en) * 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US11420995B2 (en) * 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
AU2020259997B2 (en) * 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Also Published As

Publication number Publication date
EP4232149A2 (en) 2023-08-30
WO2022084738A2 (en) 2022-04-28
EP4232149A4 (en) 2024-12-11
IL302173A (en) 2023-06-01
WO2022084738A3 (en) 2022-06-30
CA3196145A1 (en) 2022-04-28
JP2023546453A (ja) 2023-11-02
KR20230110515A (ko) 2023-07-24
MX2023004537A (es) 2023-06-15
AU2021363702A9 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
AU2020259997B2 (en) Compounds and methods for the treatment of ocular disorders
AU2021363702A9 (en) Compounds and methods for the treatment of ocular disorders
AU2020259996B2 (en) Compounds and methods for the treatment of ocular disorders
EP4232458A1 (en) Compounds and methods for the treatment of ocular disorders
EP4232034A1 (en) Compounds and methods for the treatment of ocular disorders
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法
HK40102653A (en) Compounds and methods for the treatment of ocular disorders
HK40068817A (en) Compounds and methods for the treatment of ocular disorders

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period